Drugs / antithymocyte globulins
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02728271 | Apr → Jul 2016 | eosinophilic granulomatosis with polyangiitis | Mounzer Agha | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02056938 | Jun 2014 → Feb 2017 | — | Nantes University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00538265 | May 2005 → Jan 2010 | — | University Hospital, Toulouse | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | antithymocyte globulins | “Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.” NCT02728271 ↗2“combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4)” NCT00538265 ↗ |
| Known as | ATG | “Anti-Thymocyte Globulins (ATG) as induction therapy has been described as a possible treatment for reducing the prevalence of Delayed Graft Function (DGF).” PMID 26099226 ↗ Jun 20151“combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4)” NCT00538265 ↗ |
| Route | Intravenous | “will be infused over a period of at least 6 hours” NCT00538265 ↗ |